LBA22 Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
| Autor: | Hu, X., Curigliano, G., Yonemori, K., Bardia, A., Barrios, C.H.E., Sohn, J., Levy, C., Jacot, W., Tsurutani, J., Mezei, K., Roborel de Climens, A., Wu, X., Begbie, N., Mbanya, Z., Dent, R.A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S1214-S1215 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|